What is Monte Rosa Therapeutics, Inc.'s return on equity?

Monte Rosa Therapeutics, Inc. (GLUE) reported return on equity of -32.6% in Q1 2026.

What is the long-term trend for Monte Rosa Therapeutics, Inc.'s return on equity?

Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s return on equity has grown at a -30.5% compound annual growth rate (CAGR), from -35.1% to -16.9%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Monte Rosa Therapeutics, Inc. GLUE Return on equity

Return on equity at other companies

Bristol-Myers SquibbBMY

38.8%+7.3pp

Nurix Therapeutics, Inc.NRIX

-61.4%-2.5pp

Kymera TherapeuticsKYMR

-27.1%-3.7pp

ImmunomeIMNM

-50.1%-10.8pp

Cogent Biosciences, Inc.COGT

-85.7%+1.7pp

Adaptive BiotechnologiesADPT

-24.4%-9.2pp

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

net income/total stockholders equity=-32.6%

Based on trailing twelve months.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s return on equity?: Monte Rosa Therapeutics, Inc. (GLUE) reported return on equity of -32.6% in Q1 2026.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s return on equity?: Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s return on equity has grown at a -30.5% compound annual growth rate (CAGR), from -35.1% to -16.9%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.